Tampa, Florida, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Inspirata Inc. and FUJIFILM Corporation signed an asset purchase agreement for Fujifilm to acquire Inspirata’s Dynamyx® digital pathology technology, employees and customers, building off…
Tampa, Florida, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Oncology informatics company, Inspirata, is pleased to announce the recent addition of a new key member to the company’s leadership team. Effective November 17, 2022, Laure…
Chicago, IL, July 18, 2022 (GLOBE NEWSWIRE) -- Digital pathology and cancer informatics provider Inspirata is proud to announce a new partnership with precision pathology company SpIntellx, further strengthening and diversifying…
Tampa, Florida, March 08, 2022 (GLOBE NEWSWIRE) -- Digital pathology and cancer informatics provider Inspirata announced today that it has received U.S. Food and Drug Administration (FDA) clearance for its Dynamyx digital pathology …
Bristol, United Kingdom, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology provider Inspirata and the Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance (SWAG) announced today a new partnership…
Morgantown, WV / Tampa, FL, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Today, digital pathology and cancer informatics solution provider Inspirata is pleased to announce that its Dynamyx Digital Pathology solution has officially gone live at WVU…
Las Vegas, NV / Tampa, FL, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Digital pathology and cancer informatics provider Inspirata is proud to announce their latest software release. At Pathology Visions 2021, Inspirata will showcase the new…
Tampa, Florida, July 20, 2021 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology provider Inspirata announced today a new partnership with the integrated health system OSF HealthCare. OSF HealthCare provides state-of-the-art…
London, United Kingdom, July 13, 2021 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology provider Inspirata announced today that King’s Health Partners ECMC and Guy’s and St Thomas’ NHS Foundation Trust will pilot its Trial…